Joining forces: a call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes

Affiliations

¹ Paediatric Medicines, European Medicines Agency, London, U.K. janina.karres@ema.europa.eu.
² Division of Metabolism and Endocrinology Products, U.S. Food and Drug Administration, Silver Spring, MD.
³ Office of Pediatric Therapeutics, U.S. Food and Drug Administration, Silver Spring, MD.
⁴ Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.
⁵ Department of Paediatrics, University of Cambridge, Cambridge, U.K.
⁶ Paediatric Medicines, European Medicines Agency, London, U.K.
⁷ Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Editorial

Janina Karres et al. Diabetes Care. 2014 Oct.

. 2014 Oct;37(10):2665-7.

doi: 10.2337/dc14-0494.

¹ Paediatric Medicines, European Medicines Agency, London, U.K. janina.karres@ema.europa.eu.
² Division of Metabolism and Endocrinology Products, U.S. Food and Drug Administration, Silver Spring, MD.
³ Office of Pediatric Therapeutics, U.S. Food and Drug Administration, Silver Spring, MD.
⁴ Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.
⁵ Department of Paediatrics, University of Cambridge, Cambridge, U.K.
⁶ Paediatric Medicines, European Medicines Agency, London, U.K.
⁷ Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.

No abstract available

Publication types